GPIIb/IIIa Receptor Antagonism Using Small Molecules Provides no Additive Long-Term Protection after Percutaneous Coronary Intervention as Compared to Clopidogrel Plus Aspirin

BACKGROUND: There is some controversy as to whether tirofiban or eptifibatide, two small anti-aggregating drugs (AAD), may reduce the incidence of composite ischemic events within one year in patients undergoing percutaneous coronary intervention (PCI) in the real clinical world. METHODS: We compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiariti, Michele, Saladini, Angela, Papalia, Francesco, Grillo, Placido, Nesta, Cristina, Cuturello, Domenico, Missiroli, Bindo, Puddu, Paolo Emilio
Formato: Texto
Lenguaje:English
Publicado: Bentham Open 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948151/
https://www.ncbi.nlm.nih.gov/pubmed/20922049
http://dx.doi.org/10.2174/1874192401004010151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948151/
https://www.ncbi.nlm.nih.gov/pubmed/20922049
http://dx.doi.org/10.2174/1874192401004010151

Ejemplares similares